zurück

EU-HTA

PART 11: Be ready for the phase after JCA submission

JCA submission is not the finish line – it’s the start of the most intense phase ...

Fallacy 5: EU HTA affects only Market Access and HEOR – really?

Usually, EU HTA tasks are handled by Market Access and HOER ...

Part THREE: insights into our projects

From challenging local market accesses into a global approval strategy – powered by our network ...

Access Briefing Q4/25 - German Insights

Within the Access Briefing Q4 2025, Ecker + Ecker delivers exciting decisions and developments from the German HTA landscape ...

JCA update available

We provide you with the latest regulatory update from the EMA, announced last week ...

Fallacy 4: PICO is driven by payer archetype – really?

PICO scoping is quite complex, and 27 member states (plus 3 EEA countries) are a lot ...

Our HTA insights Q4 2025 are now available 🌍

Together with our local partners and experts, we’ve analyzed HTA decisions from 13 countries across Europe and Canada from October to December 2025 ...

Tool News PART 10: The European HTA landscape in one database

Oncology products and Advanced Therapy Medicinal Products (ATMPs) are among the first drugs subjected to EU HTA ...

Fallacy 3: Impact of JCA is limited to Europe – really?

JCA is an assessment of clinical evidence on behalf of all 27 member states of the European Union, and 3 EEA countries ...

Part 2: insights into our projects

One strategy does not fit all. How our network helped a global client with country-specific expertise ...

Fallacy 2: Global Value Dossier can be used as basis for JCA – really?

Some people do argue that the Global Value Dossier (GVD) can be used as basis for JCA.

JCA updates

With the latest regulatory update from EMA announced this week we expect the first JCA Report to be published not before May 2026. ...

<
1 (aktuell)
2
3
…
6
>

Ansprechpartner

Dr. Thomas Ecker

Dr. Thomas Ecker
Tel. +49 (40) 41 33 081-10

Janine Leismann

Janine Leismann
Tel. +49 (40) 41 33 081-26